DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on November 9, 2025

Diagnos Inc. announced plans to extend the exercise period of 1,125,000 stock warrants from November 9, 2025, to August 5, 2026. This decision is contingent on approval from the TSX Venture Exchange. The warrants were issued as part of a non-brokered private placement initially announced on May 9, 2024.

The exercise price of the warrants will remain unchanged at $0.40 per common share during the extended exercise period. Diagnos stated that it will issue a follow-up release if the Exchange rejects its application for this amendment.

Diagnos specializes in early detection of eye-related health issues through the use of advanced technology and Artificial Intelligence (AI). Its aim is to provide clinicians with enhanced diagnostic capabilities and improve patient outcomes.